FDA Orphan Drug Designation Granted to Profounda Inc. for the Treatment of Acanthamoeba Keratitis with Miltefosine

ORLANDO, Fla., Dec. 19, 2016 -- (Healthcare Sales & Marketing Network) -- Profounda, Inc. ("Profounda") announced today that it has received the US Food and Drug Administration's (FDA) Orphan Drug Designation for the treatment of Acanthamoeba Ke... Biopharmaceuticals, Ophthalmology, FDA Profounda, miltefosine, Acanthamoeba Keratitis

http://salesandmarketingnetwork.com/news_release_bs.html?ID=2041977

Source: HSMN NewsFeed - December 19, 2016 Category: Pharmaceuticals Source Type: news